CDER’s Offices of New Drugs, Transitional Services Unveil 2023 Annual Reports
The FDA’s CDER has released 2023 Annual Reports for its Offices of New Drugs (OND) and Translational Services (OTS), highlighting activities that span dozens of drug approvals and guidances from…